January 17, 2018 / 12:49 PM / a year ago

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

Jan 17 (Reuters) - Aeterna Zentaris Inc:

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

* AETERNA ZENTARIS INC - ‍THROUGH SUBSIDIARY, ENTERED LICENSE AND ASSIGNMENT AGREEMENT WITH SUBSIDIARY OF STRONGBRIDGE BIOPHARMA ​

* AETERNA ZENTARIS INC - ‍ FOR AS LONG AS MACRILEN IS PATENT-PROTECTED, CO TO BE ENTITLED TO A 15 PERCENT ROYALTY ON NET SALES UP TO US$75 MILLION

* AETERNA ZENTARIS INC - ‍ FOR AS LONG AS MACRILEN IS PATENT-PROTECTED, CO TO BE ENTITLED TO A 18 PERCENT ROYALTY ON NET SALES OVER US$75 MILLION

* AETERNA ZENTARIS - ‍COMMITTEE WITH OVERSIGHT OF PEDIATRIC DEVELOPMENT PGM TO BE MADE OF 4 PERSONS,2 OF WHOM TO BE APPOINTED BY EACH OF STRONGBRIDGE, CO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below